Advertisement

Search Results

Advertisement



Your search for George W. Sledge, Jr, MD matches 25 pages

Showing 1 - 25


breast cancer

Expert Point of View: George W. Sledge, Jr, MD

The results of monarchE were discussed by George W. Sledge, Jr, MD, Professor of Medicine and Chief of Oncology at Stanford University Medical Center, who offered some possibilities as to why its results were positive and those for palbociclib, in the phase III PALLAS trial, were “resoundingly...

ASCO as a Public Organization: No Longer Hiding Our Lamp Under a Basket

Like many professional organizations in the public sphere, ASCO regularly confronts policy issues. Because we are a large organization, and because we represent many constituencies, we are frequently called upon to offer our advice to the federal government. Our members must sometimes wonder where...

ASCO, Conquer Cancer Honor Leaders in Cancer Care With 2020 Special Awards

ASCO and Conquer Cancer, the ASCO Foundation®, are proud to recognize the winners of ASCO’s 2020 Special Awards and Conquer Cancer’s Women Who Conquer Cancer Mentorship Awards. The recipients of these awards have worked to transform cancer care around the world. David A. Karnofsky Memorial Award...

ASCO Presidents Through the Years: Past, Present, and Future

2020–2021: Lori J. Pierce, MD, FASTRO 2019–2020: Howard “Skip” Burris, III, MD, FACP 2018–2019: Monica M. Bertagnolli, MD 2017–2018: Bruce E. Johnson, MD 2016–2017: Daniel F. Hayes, MD 2015–2016: Julie Vose, MD, MBA 2014–2015: Peter P. Yu, MD 2013–2014: Clifford A. Hudis, MD 2012–2013: Sandra M....

breast cancer

MONARCH 2: Interim Analysis of Overall Survival With Abemaciclib/Fulvestrant in Hormone Receptor–Positive, HER2-Negative Breast Cancer

As reported in JAMA Oncology by George W. Sledge, Jr, MD, and colleagues, an interim analysis of overall survival in the phase III MONARCH 2 trial has shown a significant advantage for abemaciclib plus fulvestrant vs fulvestrant alone in women with advanced hormone receptor–positive, HER2-negative...

ASCO Through the Years: Past Presidents

Over the years many great oncology leaders have served at the helm as ASCO President. We recognize these individuals here, and extend our gratitude for their service and efforts to champion high-quality cancer care. 2018-2019: Monica M. Bertagnolli, MD 2017-2018: Bruce E. Johnson, MD 2016-2017:...

2018 William L. McGuire Award Nominations Now Being Accepted

Nominations are now being accepted for the William L. McGuire Award and Lectureship. The award is given annually at the San Antonio Breast Cancer Symposium in recognition of an investigator whose extraordinary and sustained achievements in translational and/or clinical research have made an impact ...

breast cancer

Adding Abemaciclib to Fulvestrant in Hormone Receptor–Positive, HER2-Negative Breast Cancer

In the phase III MONARCH 2 trial reported at the recent ASCO Annual Meeting and in the Journal of Clinical Oncology by Sledge et al, the addition of the selective cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor abemaciclib to fulvestrant (Faslodex) improved progression-free survival in hormone...

Susan G. Komen Names Eight Advisors to Guide Breast Cancer Research Program

Susan G. Komen announced new advisory roles for eight leaders in breast cancer who will guide the organization’s education and advocacy work, public health efforts, and help direct Komen’s $920 million research program. On April 1, Jennifer A. Pietenpol, PhD, of Vanderbilt-Ingram Cancer Center,...

ASCO Presidents Through the Years

2016–2017 Daniel Hayes, MD 2015–2016 Julie Vose, MD, MBA 2014–2015 Peter Paul Yu, MD, FACP 2013–2014 Clifford A. Hudis, MD, FACP 2012–2013 Sandra M. Swain, MD 2011–2012 Michael P. Link, MD 2010–2011 George W. Sledge, Jr, MD 2009–2010 Douglas W. Blayney, MD 2008–2009 Richard...

Expert Point of View: 3-Year Screening Interval Safe for Women with HPV-negative and Normal Pap Tests, Data Show

This is a wonderful population-based study… that makes us comfortable with the current recommendations. The issue of how frequently one or the other test should be used is an evolving area,” said George W. Sledge, Jr, MD. Dr. Sledge is ASCO Immediate Past President. Dr. Sledge pointed out that...

Accelerating Progress vs Cancer

At the opening press briefing and throughout ASCO’s 47th Annual Meeting, presenters marked the 40th anniversary of the National Cancer Act by highlighting the significant progress made in cancer treatment over the past 4 decades, the major challenges ahead, and new research models to find better...

Expert Point of View: Smoking and Lack of Exercise Increase Risk of Some Cancers, but Moderate Alcohol Consumption Reduces Colon Cancer Risk

At a press conference where results of the study by Land and colleagues were released, George W. Sledge, Jr, MD, said, “This study highlights the importance of lifestyle factors. We need to think about encouraging women who engage in unhealthy behaviors that place them at risk for cancer to change...

ASCO Connection Adds New Columnists, Launches Group Creation Option

ASCO’s professional networking site, ASCOconnection.org, continues to build depth in areas of interest to the oncology community, adding as its newest commentator ASCO President Michael P. Link, MD, the Lydia J. Lee Professor in Pediatric Oncology at Stanford University School of Medicine, as well...

ASCO’s Immediate Past President Helps Build Future of Cancer Research and Care by Supporting Conquer Cancer Foundation

George W. Sledge, Jr, MD, has been treating patients with breast cancer, and pursuing research in the field, for more than 30 years—the last few electrified by a rapid proliferation of knowledge. “We have so much to offer our patients today,” says Dr. Sledge, who serves as Ballve-Lantero Professor...

Reflections from The ASCO Post

The editors gratefully acknowledge all contributors to The ASCO Post and thank the columnists who contributed to Volume 2, January–December 2011: Al B. Benson III, MD, FACP Richard Boxer, MD, FACS Carlton G. Brown, RN, PhD, AOCN Barrie R. Cassileth, PhD E. David Crawford, MD Emil J. Freireich, MD, ...

Pre–Annual Meeting Seminar Series Kicks Off

This year, ASCO is cosponsoring a new series of intimate, discussion-based seminars to be held just before the start of the Annual Meeting in June. The three seminars, which start at 1:00 PM on Thursday, May 31, and continue through noon on Friday, June 1, the first day of the Annual Meeting, are: ...

SIDEBAR: Expect Questions from Your Patients

For now, genomic sequencing seems to have a greater presence in the news than in the clinic. What can physicians tell their patients who ask about genetic testing to identify mutations driving cancer growth?  “The real answer is that when you get down to it, genomics is like any other test,”...

Genomics vs Site of Cancer Origin as Basis for Treatment of Cancer Is ‘False Dichotomy’

In the News focuses on media reports that your patients may have questions about at their next visit. This continuing column will provide summaries of articles in the popular press that may prompt such questions, as well as comments from colleagues in the field. Despite recent news reports...

The Promise of Genomics

My year as President of ASCO was one of momentous change, not just for ASCO, but for health care and for cancer biology as well. The theme of my Presidency was Patients, Pathways, and Progress. “Pathways” referred to the molecular pathways that are becoming increasingly important in the targeted...

ASCO Through the Years: Past Presidents

This year ASCO celebrates it's 50th Anniversary. Here is a list of past ASCO Presidents over these 50 years: 2014-2015: Peter P. Yu, MD 2013-2014: Clifford A. Hudis, MD 2012-2013: Sandra M. Swain, MD, FACP 2011-2012: Michael P. Link, MD 2010-2011: George W. Sledge, Jr, MD 2009-2010: Douglas W....

Expert Point of View: George W. Sledge, Jr, MD

In his commentary on the ALTTO results, George W. Sledge, Jr, MD, Professor of Medicine and Director of the Division of Oncology at Stanford University, reminded attendees that the announcement of the first results for adjuvant trastuzumab, which occurred at the 2005 ASCO Annual Meeting, was “a...

breast cancer

ALTTO Trial Finds Dual Anti-HER2 Therapy No Better Than Trastuzumab Alone

The highly anticipated results from the phase III ALTTO trial show no additional benefit for adding lapatinib (Tykerb) to trastuzumab (Herceptin) in the adjuvant treatment of HER2-positive breast cancer.1 The results were presented at the 2014 ASCO Annual Meeting’s Plenary Session by Martine J....

breast cancer

Triple Negative Breast Cancer Foundation Works to Change the Treatment Landscape of an Aggressive Form of Breast Cancer

Hayley Dinerman, Cofounder and Executive Director of the Triple Negative Breast Cancer Foundation, remembers how she and a group of close female friends first learned about the devastating effects of triple-negative breast cancer. It was 2005 when these new mothers, who had recently formed a...

breast cancer

Experts Debate: Can We Cure Metastatic Breast Cancer?

Can metastatic breast cancer ever be cured? This issue was debated at the 32nd Annual Miami Breast Cancer Conference by two experts in the field: George W. Sledge, Jr, MD, Professor of Medicine at Stanford University Medical Center, Palo Alto, California, and Clifford A. Hudis, MD, Chief of the...

Advertisement

Advertisement



Advertisement